Radioiodine therapy accelerates apoptosis in peripheral blood lymphocytes of patients with differentiated thyroid cancer

As it is known that genetic polymorphisms of glutathione S-transferases (GST) have been associated with a variety of human diseases including cancer, we have analyzed the impact of GSTT1 and GSTM1 null genotypes on the risk of development of differentiated thyroid cancer (DTC) and cytogenetic changes in peripheral blood lymphocytes of DTC patients before and after radioiodine therapy. The polymorphism of GSTT1 and GSTM1 genes were genotyped using multiplex polymerase chain reaction (PCR) and cytokinesis - block micronucleus (MN) assay to assess cytogenetic changes. GSTT1 and GSTM1 null were predominantly found in patients, but statistical significance was observed only for GSTT1 null. The null genotypes increased risk of development of DTC; GSTT1 null a 4.5 times (p < 0.05), GSTM1 null about 3 times but on the border of statistical significance (p = 0.057), while combination of dual null genotypes almost 7 times (p < 0.05) increased risk. No significant effects of the null genotypes as well as their interactions with potential modifiers of MN (diagnose, age, gender and smoking habits) were observed on both baseline and radioiodine-induced values of MN and cytokinesis block proliferation index (CBPI) in DTC patients. Results suggest that both GSTT1 and GSTM1 null genotypes increased risk for DTC but to a greater extent GSTT1 null. Null genotypes of GSTT1 and GSTM1 did not have potential to influence baseline and radioiodine-induced values of MN and CBPI, so that absence of T1 and M1 isoenzymes did not cause increased mutagen sensitivity of PBLs of DTC patients.

Download Full-text

Thyroglobulin mRNA quantification in the peripheral blood is not a reliable marker for the follow-up of patients with differentiated thyroid cancer

Acta Endocrinologica ◽

10.1530/eje.0.1470575 ◽

2002 ◽

pp. 575-582 ◽

Cited By ~ 31

Author(s):

M Eszlinger ◽

S Neumann ◽

L Otto ◽

R Paschke

Keyword(s):

Thyroid Cancer ◽

Real Time ◽

Peripheral Blood ◽

Differentiated Thyroid Cancer ◽

Mononuclear Cells ◽

Radioiodine Therapy ◽

Rt Pcr ◽

Beta Actin ◽

Citrate Blood

BACKGROUND: The detection of serum thyroglobulin (Tg) by immunoassay is widely used to detect residual, recurring or metastatic thyroid carcinoma tIssue in patients with differentiated thyroid cancer (DTC) after total thyroidectomy and radioiodine therapy. However, this method requires thyroid hormone withdrawal to increase sensitivity and is limited by the interference of anti-Tg antibodies. To solve these problems, the detection of Tg mRNA from circulating thyroid cells by reverse transcription (RT)-PCR has been suggested as an alternative method. However, different previous reports show discrepant conclusions as to the clinical usefulness of Tg mRNA quantification. METHODS: We compared three methods of blood collection and RNA extraction, and quantified Tg mRNA (by real time RT-PCR) in the peripheral blood of a) probands without thyroid disease (n=42), patients with b) thyroid autonomy (n=15), c) Graves' disease (n=22), d) euthyroid goiter (n=6), and in DTC-patients after thyroidectomy and radioiodine therapy e) with (n=16) and f) without (n=37) metastasis. As the use of citrate blood in combination with a subsequent separation of mononuclear cells showed a significantly better RNA yield than the extraction of RNA from EDTA or citrate blood without the separation of mononuclear cells, this was the method used. Total RNA was reverse transcribed with random hexamer primers and Tg mRNA was amplified by real time RT-PCR using specific primers and hybridization probes. The Tg mRNA concentrations were normalized to beta-actin mRNA concentrations. RESULTS: Mean circulating Tg mRNA for each group detailed above, expressed as the ratio of Tg to beta-actin concentrations x 1000, were: a) 2.3 (range 0.03-70.89), b) 0.25 (range 0.02-0.55), c) 0.31 (range 0.05-1.36), d) 0.18 (range 0.08-0.35), e) 0.57 (range 0.03-3.03) and f) 0.17 (range 0.02-0.60). Furthermore, we found no correlation between serum Tg and Tg mRNA. CONCLUSIONS: In summary, our data do not show significant differences in Tg mRNA expression between the investigated groups. Therefore, the detection and quantification of Tg mRNA in peripheral blood is unlikely to be suitable for the follow-up of DTC.

Download Full-text

Cytogenetic Damage in the Peripheral Blood Lymphocytes of Thyroid Cancer Patients during Pre and Post 131I Therapy

Journal of Medical Science And clinical Research ◽

10.18535/jmscr/v4i9.72 ◽

2016 ◽

Author(s):

Uma Bhartiya ◽

Keyword(s):

Thyroid Cancer ◽

Cancer Patients ◽

Peripheral Blood ◽

Peripheral Blood Lymphocytes ◽

131I Therapy ◽

Cytogenetic Damage ◽

Blood Lymphocytes

Download Full-text

Correlation between Micronuclei Frequency in Peripheral Blood Lymphocytes and Retention of 131-I in Thyroid Cancer Patients

The Tohoku Journal of Experimental Medicine ◽

10.1620/tjem.229.115 ◽

2013 ◽

Vol 229 (2) ◽

pp. 115-124 ◽

Cited By ~ 6

Author(s):

Olgica B. Vrndic ◽

Olivera M. Milo^|^scaron;evic-Djordjevic ◽

Ljiljana C. Mijatovic Teodorovic ◽

Marija Z. Jeremic ◽

Ivana M. Sto^|^scaron;ic ◽

...

Keyword(s):

Thyroid Cancer ◽

Cancer Patients ◽

Peripheral Blood ◽

Peripheral Blood Lymphocytes ◽

Blood Lymphocytes

Download Full-text

Blood cells in thyroid cancer patients: a possible influence of apoptosis

Open Medicine ◽

10.1515/med-2016-0017 ◽

2016 ◽

Vol 11 (1) ◽

pp. 87-92

Author(s):

Olgica B. Vrndic ◽

Predrag M. Djurdjevic ◽

Danijela D. Jovanovic ◽

Ljiljana C. Mijatovic Teodorovic ◽

Irena R. Kostic ◽

...

Keyword(s):

Thyroid Cancer ◽

Blood Cell ◽

Cancer Patients ◽

Peripheral Blood ◽

Blood Cells ◽

Peripheral Blood Lymphocytes ◽

Color Flow ◽

Blood Lymphocytes ◽

Cell Counts ◽

Blood Cell Counts

AbstractThe side effects of radioactive iodine (131-I) treatment of differentiated thyroid cancer (DTC) patients include reduction of peripheral blood cell counts. The aim of this study was to analyze some potential changes in blood cell counts of DTC patients after 131-I therapy, especially CD3-positive, CD19-positive, and CD56-positive peripheral blood lymphocytes (PBL), as well as the possible role of apoptosis in selected lymphocyte populations. The study group included 24 thyroid cancer patients and 24 control subjects. Peripheral blood samples from patients and controls were analyzed using 5-color flow cytometry. Apoptotic cells were detected using an Annexin V-FITC/7-AAD kit. There was a statistically significant decrease of all blood cells after the 131-I therapy. The CD19+ B lymphocyte population was the most affected (5.82 ± 3.21% before therapy vs. 3.93 ± 2.60% after therapy, p = 0.008). This decrease was correlated with the degree of apoptosis of peripheral blood lymphocytes (Spearman’s r = 0.563, p =0.013). We concluded that 131-I therapy of DTC patients led to a decrease of all peripheral blood cells, especially CD19+ B lymphocytes. This directly correlated with apoptosis of PBLs, indicating that radiation damage to B cells leads to subsequent elimination by apoptosis.

Download Full-text